Fri, Jul 25, 2014, 9:24 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Omeros Corporation (OMER) Message Board

  • Dooper55 Dooper55 Mar 27, 2012 7:45 AM Flag

    Omeros Names Dr. Patrick Gray as Scientific Fellow

    March 27, 2012 07:01 AM EDT

    SEATTLE, March 27, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the appointment of Patrick W. Gray, Ph.D. to the position of scientific fellow.

    "Pat has an impressive track record of identifying commercially successful programs and products early in their development cycle," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "In his role as scientific fellow, Pat will be able to leverage his unique and deep expertise across our research and development matrix. We are pleased that he has joined our senior management team, and we look forward to him contributing to our success."

    "The scientific depth and commercial potential of Omeros' programs are remarkable," stated Patrick W. Gray, Ph.D., Omeros' scientific fellow. "Omeros has a strong and experienced management team, and I look forward to helping the Company continue to transform its pipeline of programs into marketed products."

    Dr. Gray brings to Omeros more than 30 years of experience in the biotechnology industry. He joined Omeros after serving from 2007 until 2012 as the chief scientific officer of Accelerator Corporation, a biotechnology-company investor and incubator affiliated with Amgen Ventures, ARCH Venture Partners, OVP Ventures Partners and the Institute for Systems Biology. Prior to Accelerator, Dr. Gray was the chief executive officer of nura, inc., a privately held biotechnology company acquired by Omeros in 2006. Before nura, he held senior scientific and management positions at Genentech, Inc., ICOS Corporation and MacroGenics, Inc.

    Dr. Gray's career accomplishments include the first cloning and characterization of the following important proteins: Hepatitis B surface antigen, Interferon-gamma, multiple Interferon-alpha genes, Lymphotoxin (TNF-beta) Bactericidal Permeability Increasing Protein, Lipopolysaccharide (LPS)-Binding Protein, Platelet Activating Factor Acetylhydrolase, CCR5 (subsequently shown to be the HIV co-receptor) and Macrophage Derived Chemokine. Five of these proteins are approved human pharmaceuticals or led to clinical trials, and others are targets for therapeutic monoclonal antibodies. Dr. Gray also participated in the discovery and development of Cialis®. Dr. Gray received his Ph.D. in chemistry from the University of Colorado and his B.S. in biology from the University of Oregon.

 
OMER
13.98-0.07(-0.50%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.